This Could Be A Monumental Year For The 340B Program

Law360, New York (January 3, 2016, 9:08 AM ET) -- Elizabeth S. Elson



Anil Shankar During 2015, the 340B Drug Pricing Program was the focus of legal, regulatory and political activities, including the proposal of significant new “mega guidance,” court battles addressing the scope of the government’s authority to regulate the program, an increase in audits of participating providers (covered entities) and multiple congressional hearings discussing the future of the program. These activities will continue in 2016, which is likely to be a monumental year for the program.



The 340B program provides significant discounts on the cost of...

To view the full article, register now.